WATCH: Brain‑Computer Interfaces: Current Applications & Emerging Directions

Brain‑computer interfaces (BCIs) and related neural interface technologies have gained significant media attention, but their clinical meaning is often misunderstood. In this whiteboard overview, Dr. Damiano Barone, a Houston Methodist neurosurgeon and scientist specializing in functional and peripheral nerve surgery, breaks down the terminology, mechanisms and real‑world applications of these systems.

Rather than focusing on speculative or futuristic claims, the discussion centers on how today's neural interfaces can actually interact with the nervous system. From non‑invasive EEG to intracortical and spinal cord devices, different approaches offer different trade‑offs in precision, invasiveness and durability.

Importantly, while some neural interfaces are already well established in clinical practice, true BCIs remain largely in the clinical and laboratory research domain. Understanding where these technologies are effective — and where they still fall short — is essential for clinicians evaluating their role in patient care.

Key highlights

• Neurotechnology is the broad umbrella, with neural interfaces as a specific subset. Neurotechnology includes any technology interacting with the nervous system, such as imaging tools, wearable devices and surgical systems. Neural interfaces specifically involve direct electrical interaction between electrodes and neural tissue, through either stimulation, recording or both.

• Brain‑computer interfaces primarily focus on recording, not stimulation. BCIs are generally one‑way systems that record neural signals and translate them into computer outputs, such as controlling a cursor or enabling speech synthesis. This distinguishes them from bidirectional or closed‑loop systems that both record from and stimulate the nervous system.

• Invasiveness directly affects signal quality and clinical trade‑offs. Non‑invasive approaches like EEG sample large populations of neurons but lack precision. In contrast, intracortical and deep brain devices can record from individual neurons, offering higher fidelity at the cost of greater invasiveness and biological risk.

• Current clinical mainstays are neural interfaces, not BCIs. Deep brain stimulation (DBS) and spinal cord stimulation (SCS) are widely used clinically but are not classified as BCIs. They function through targeted stimulation to modulate neural pathways, such as reducing tremor or blocking pain signals.

• BCIs show promise for speech and motor restoration but remain largely investigational. High‑density recording electrodes are being used in research settings to decode speech and motor intent in patients, enabling communication or control of external devices. These applications have demonstrated feasibility in clinical studies but are not yet routine tools in practice.

• Foreign body reaction is a major barrier to long‑term implantation. Implanted electrodes trigger inflammatory and scarring responses that degrade signal quality over time. Until this biological response can be mitigated, durable, lifelong BCIs remain a significant challenge.

• Engineering constraints limit scalability and patient usability. Current systems require large computational resources and high energy consumption. Miniaturization, onboard processing and sustainable power solutions are critical hurdles before widespread clinical adoption is feasible.

• The clinical goal is restoration, not enhancement. The long‑term objective of neural interface research is to restore lost communication, movement and function following neurologic injury — not to enhance normal human capabilities. This distinction remains central to both ethical considerations and clinical translation.